10 research outputs found
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies
3-Thiabicyclo[3.2.0]hept-6-ene 3,3-Dioxide:A Novel Synthon for cis-1,2-Divinyl Intermediates and Derived Seven-membered Ring Heterocycles
Unusual Effect of a Remote SO<sub>2</sub> Group on the Reactivity of the Double Bond in Unsaturated Cyclic Sulphones towards Ethoxycarbonylnitrene
Chemical Repercussions of Orbital Interactions through Bond and through Space:The Reactivity of the Double Bond in Unsaturated Cyclic Sulphones towards Aziridine Formation and Epoxidation
Chemical Repercussions of Orbital Interactions through Bond and through Space:Effect of Remote Substituents on the Addition of Nitrenes to Bicyclic Olefins
Recommended from our members
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
As the mean age of the global population increases, breast cancer in older individuals will be increasingly encountered in clinical practice. Management decisions should not be based on age alone. Establishing recommendations for management of older individuals with breast cancer is challenging because of very limited level 1 evidence in this heterogeneous population. In 2007, the International Society of Geriatric Oncology (SIOG) created a task force to provide evidence-based recommendations for the management of breast cancer in elderly individuals. In 2010, a multidisciplinary SIOG and European Society of Breast Cancer Specialists (EUSOMA) task force gathered to expand and update the 2007 recommendations. The recommendations were expanded to include geriatric assessment, competing causes of mortality, ductal carcinoma in situ, drug safety and compliance, patient preferences, barriers to treatment, and male breast cancer. Recommendations were updated for screening, primary endocrine therapy, surgery, radiotherapy, neoadjuvant and adjuvant systemic therapy, and metastatic breast cancer
Position paper by the UKCCCR Elderly Cancer Patients in Clinical Trials Working Group
Following discussions at the UKCCCR Trials Committee in 1995, a decision was taken during early 1996 to set up a Working Group to consider the management of elderly cancer patients and their entry into clinical trials. This decision was subsequently endorsed by the Main Committee of the UKCCCR. Dr Peter Harper (Guy’s Hospital, London) kindly agreed to chair the Group and the other members were then recruited (see below). The Group met for the first time in July 1996 and on five further occasions up until October 1997. This short paper summarizes the proceedings to date